Agreement to Progress Rare Disease Development in China

Martin Whitaker

首页> 外文期刊>International labmate >Agreement to Progress Rare Disease Development in China

【24h】

Agreement to Progress Rare Disease Development in China

机译：协议进展中国罕见疾病发展

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Pharmaceutical companies Diurnal Group and Citrine Medicine have established a licencing agreement for Diurnal's Alkindi (hydrocortisone granules in capsules for opening) covering China, Hong Kong, Taiwan and Macau. Under the terms of the licence agreement Cardiff-based Diurnal, targeting patient needs in chronic endocrine (hormonal) conditions, receives an upfront payment of $0.5 million and $12.75 million in additional cash payments arising from certain regulatory and sales milestones, as well as tiered royalties on sales ranging from low to mid double-digits. Citrine, co-founded by Vivo Capital, F-Prime Capital and Eight Roads Ventures, is focused on creating a therapeutic platform to deliver rare disease drugs to the Chinese market and to develop the first ever rare disease ecosystem in the country. It will be responsible for obtaining registration for Alkindi as a treatment for paediatric patients in China and for all commercialisation activities, including pricing and reimbursement. Initially utilising the product from Diurnal's European supply chain, it has an option to establish its own supply chain in China in the future. It is estimated that congenital adrenal hyperplasia (CAH) occurs in 1 in 6,084 births in China [1]. CAH is a group of genetic conditions that limit hormone production in the adrenal glands and was identified a rare disease by the Chinese health authorities in May 2018.

机译：None

著录项

来源
《International labmate》 |2021年第2期|共1页
作者
Martin Whitaker;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类仪器、仪表;
关键词

相似文献

外文文献
中文文献
专利

1. Experiences and Achievements in the Development of Human Rights in China in the Past 40 Years of Reform and Opening-up— A Summary of Viewpoints on the Seminar on Reform and Opening-up and the Progress of the Development of Human Rights in China [J] . WANG Xigen, CHEN Yan, CHEN Feng 人权：英文版 . 2018,第005期
2. CHALCO and Guangxi Nonferrous,Grirem Signed Framework Agreement for Rare Earth Development [J] . 中国有色金属月刊：英文版 . 2011,第004期
3. Chalco and China Development Bank Signed Development-Oriented Financial Cooperation Agreement [J] . 中国有色金属月刊：英文版 . 2015,第003期
4. Progress Toward Implementing the Sendai Framework, the Paris Agreement, and the Sustainable Development Goals: Policy from Aotearoa New Zealand [J] . Wendy S.A.Saunders, Scott Kelly, Suzanne Paisley, 国际灾害风险科学学报：英文版 . 2020,第002期
5. Development and progress of the National Congenital Anomaly and Rare Disease Registration Service [J] . Stevens Sarah, Miller Nicola, Rashbass Jem Archives of disease in childhood . 2018,第3期

机译：国家先天性异常和罕见疾病登记服务的发展与进展
6. The German plan for rare diseases: a development in progress [J] . Johann Mathias Graf von der Schulenburg Orphanet journal of rare diseases . 2010,第S1期

机译：德国罕见病计划：发展中
7. Current status of premature mortality from four non-communicable diseases and progress towards the Sustainable Development Goal target 3.4: a population-based study in northeast China, 2004–2017 [J] . Liu Li, Li Yanxia, Song Junmin, BMC Public Health . 2021,第1期

机译：来自四种非传染病的早产儿的现状以及对可持续发展目标目标的进展3.4：2004 - 2017年东北地区的基于人口的研究
8. THE INTERNAL DOSE OF RARE EARTH ELEMENTS AND ITS EFFECTS ON NEUROBEHAVIORAL DEVELOPMENT OF CHILDREN AGED 0-3YRS IN RARE EARTH ORES OF SOUTH CHINA [C] . . 2001

机译：中国南方稀土中0-3岁儿童稀土元素的内部剂量及其对神经行为发育的影响
9. How Does the Social World Shape the Experience of a Rare Disease? Social Position and the Development, Progression, and Medical Care for People with Amyotrophic Lateral Sclerosis [D] . Andersen, Jennifer Audrey. 2020

机译：社会世界如何塑造罕见疾病的经验？社会地位和发展，进展和医疗和医疗，对肌营养的外侧硬化症的人
10. The progress of challenges faced by and future of rare disease patient organizations in China [O] . Rufang Huang, Yunshu Wei, Jiahao Hu, 2019

机译：中国罕见病患者组织的进展面临的挑战和未来
11. The progress of, challenges faced by, and future of rare disease patient organizations in China [O] . Rufang Huang, Yunshu Wei, Jiahao Hu, 2019

机译：中国面临的挑战的进展与中国稀有疾病患者组织的未来
12. Workshop. Projects on Rare Diseases funded within the Bilateral Agreement Italy (Istituto Superiore di Sanita) on Joint Research and Development of Public Health Actions. Held in Istituto Superiore di Sanita Rome, on October 29-21, 2008. Abstract Book [R] . Taruscio, D., Salvatore, M. 2009

机译：作坊。关于罕见疾病的项目由意大利双边协议（Istituto superiore di sanita）资助，负责公共卫生行动的联合研究和开发。 2008年10月29日至21日在Istituto superiore di sanita罗马举行。摘要书

Agreement to Progress Rare Disease Development in China

摘要

著录项

相似文献

相关主题

期刊订阅